Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
- PMID: 20581241
- DOI: 10.1136/gut.2009.194472
Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
Abstract
Objective: To evaluate immunosurveillance/editing in colorectal cancer.
Design: Transformation stimulates the production of interferon gamma (IFNgamma) which signals via the IFNgamma receptor (IFNGR1) on tumours. This results in stimulation of nuclear STAT1 (nSTAT1), inhibition of tumour growth and upregulation of major histocompatibility complex (MHC) while promoting T cell extravasation. In contrast, downregulation of MHC class I by allele loss results in loss of T cell recognition. A tissue microarray of 462 colorectal tumours with mean follow-up of 42 months (range 1-116) was stained by immunohistochemistry for markers which predict immunosurveillance/editing.
Results: The presence of a high level of intratumoral T cells (ITTC) correlated with improved survival compared with a low level of ITTC, with a mean difference in survival of 16.3 months (p=0.006). There was a direct correlation between nSTAT1 expression and ITTC (p<0.001). Patients whose tumours had a high level of ITTC and nSTAT1 survived 20 months longer than those whose tumours had a low level of ITTC and no nSTAT1. A strong correlation was seen between ITTC and MHC class I expression (p=0.0002). A mean survival advantage of 26.1 months was seen in patients whose tumours had strong MHC I expression and high levels of ITTC over those who had weak MHC I and low levels of ITTC (log-rank test=12.023, p=0.034). Both MHC I and ITTC are independent predictors of good survival.
Conclusions: ITTC, nSTAT1 and strong MHC class I expression on tumours identify patients with improved survival and an intact tumour immune system that may benefit from immunotherapy. Conversely, loss of these markers identifies patients whose tumours have escaped immunosurveillance and are unlikely to benefit from immunotherapy.
Similar articles
-
The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Eur J Surg Oncol. 2012. PMID: 22721580 Review.
-
Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20. Gut. 2009. PMID: 19022917
-
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?Clin Cancer Res. 2008 Apr 1;14(7):2028-35. doi: 10.1158/1078-0432.CCR-07-4554. Clin Cancer Res. 2008. PMID: 18381941
-
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.Cancer Immun. 2007 Aug 13;7:12. Cancer Immun. 2007. PMID: 17691714 Free PMC article. Review.
-
Natural killer cells infiltrating colorectal cancer and MHC class I expression.Mol Immunol. 2005 Feb;42(4):541-6. doi: 10.1016/j.molimm.2004.07.039. Mol Immunol. 2005. PMID: 15607811
Cited by
-
CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis.J Transl Med. 2024 May 15;22(1):460. doi: 10.1186/s12967-024-05284-7. J Transl Med. 2024. PMID: 38750462 Free PMC article.
-
Pan-cancer analysis of Sushi domain-containing protein 4 (SUSD4) and validated in colorectal cancer.Aging (Albany NY). 2024 Apr 4;16(7):6417-6444. doi: 10.18632/aging.205712. Epub 2024 Apr 4. Aging (Albany NY). 2024. PMID: 38579174 Free PMC article.
-
Ionizable Lipid Nanoparticle-Mediated TRAIL mRNA Delivery in the Tumor Microenvironment to Inhibit Colon Cancer Progression.Int J Nanomedicine. 2024 Mar 14;19:2655-2673. doi: 10.2147/IJN.S452896. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38500680 Free PMC article.
-
Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review).Mol Med Rep. 2024 Mar;29(3):39. doi: 10.3892/mmr.2024.13163. Epub 2024 Jan 19. Mol Med Rep. 2024. PMID: 38240082 Free PMC article. Review.
-
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine Restriction in a Colorectal Cancer Model.Cancers (Basel). 2023 Sep 7;15(18):4467. doi: 10.3390/cancers15184467. Cancers (Basel). 2023. PMID: 37760436 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous